

5 – 8 September 2007  
Barcelona, Spain  
Hotel Fira Palace

second announcement

FIRST WORLD MEETING  
OF INTERDISCIPLINARY  
MELANOMA / SKIN CANCER CENTERS

Under the auspices of



European Association of Dermatologic Oncology

[www.melanomacentersmeeting.com](http://www.melanomacentersmeeting.com)

**T**he **First World Meeting of Interdisciplinary Melanoma/Skin Cancer Centers**, to take place in **Barcelona Spain** in **September 2007**, will be a unique opportunity for melanoma clinicians and researchers, who are part of multidisciplinary melanoma /skin cancer centers to interact, learn from one another, establish collaborations and set an agenda for the further evolution of multidisciplinary melanoma care and research.

The conference will feature **Plenary Session** speakers who are recognized experts in melanoma treatment and research. These Plenary Sessions will form the scientific backdrop for the meeting, and will highlight problem areas and opportunities in melanoma today. These Plenary Sessions will set the stage for a series of **Breakout Sessions** conducted by clinical and research experts, designed to focus attention and lead to new collaborative approaches in key areas where melanoma centers should be taking the lead.

The Breakout Sessions will address the following topics:

- **Melanoma Education, Prevention and Training**

**Goals:** To facilitate international collaborations among multidisciplinary melanoma centers in melanoma patient education and early detection, and in melanoma prevention techniques and research. To develop strategies for further melanoma treatment and research by establishing melanoma training opportunities (eg, clinical or postdoctoral research fellowships) for clinicians and researchers in collaborative multidisciplinary melanoma centers.

- **Melanoma Tumor Tissue Procurement and Collaborative Research**

**Goals:** To develop improved strategies for procuring fresh frozen and paraffin-embedded tissue from primary melanoma specimens that maximize both research opportunities and patient safety. To establish improved networks for collaboration among multidisciplinary melanoma centers worldwide, with a particular focus on increasing the level of collaboration between North American, Australian and European melanoma centers and between melanoma centers and existing cooperative oncology clinical research groups in North America and Europe.

- **Melanoma Treatment and Clinical Trials**

**Goals:** To foster the more rapid dissemination of innovative melanoma diagnostic, imaging and treatment techniques among the world's melanoma centers. To establish networks for the rapid conduct of cutting edge clinical trials and biomarker correlative studies requiring large groups of patients with adequate follow up. To establish clinician researcher collaborations that allow the integration of correlative scientific studies into existing and future clinical trials conducted through the melanoma centers and the cooperative oncology clinical research groups.

After the initial specialty based session, subsequent sessions would be topic based and would include a mixture of specialists in each session, carrying forward the discussions started in the specialty breakout. Finally, "writing committees" selected during the last breakout session will be formed to summarize the discussions on each topic and provide a series of concrete suggestions and strategies, as well as ideas for developing funding sources when relevant.

The final "product" of these breakout sessions, and the Meeting as a whole, will be the written blueprint for the world's multidisciplinary centers to move forward in a collaborative fashion to improve melanoma education, prevention, training, clinical care and research.

We look forward to seeing you in **Barcelona in September!**



**Josep Malvehy** Barcelona, Spain



**Claus Garbe** Tuebingen, Germany



**Vernon Sondak** Tampa, Florida, USA



**John Thompson** Sydney, Australia

## Organizing Committee

Josep Malvehy. Barcelona, Spain  
Claus Garbe. Tuebingen, Germany  
Vernon Sondak. Tampa, Florida, USA  
John Thompson. Sydney, Australia

## Local Scientific Committee

Rafael Botella. Valencia, Spain  
Cristina Carrera. Barcelona, Spain  
Teresa Castel. Barcelona, Spain  
Julián Conejo-Mir. Sevilla, Spain  
Carles Conill. Barcelona, Spain  
Carlos Ferrándiz. Barcelona, Spain  
Pedro Gascón. Barcelona, Spain  
Carmen Herrero. Barcelona, Spain  
Pablo Lázaro. Madrid, Spain  
Cristina Mangas. Barcelona, Spain

Maribel Marmol. Barcelona, Spain  
Rosa Martí. Lleida, Spain  
Salvador Martín-Algarra. Pamplona, Spain  
Susana Puig. Barcelona, Spain  
Ramon Rull. Barcelona, Spain  
Marcelo Sánchez. Barcelona, Spain  
Sergi Vidal-Sicart. Barcelona, Spain  
Antonio Vilalta. Barcelona, Spain  
Ramon Vilella. Barcelona, Spain

## Faculty

Sanjiv Agarwala. Bethlem, USA  
Giuseppe Argenziano. Naples, Italy  
Jürgen Becker. Wuerzburg, Germany  
Antonio Buzaid. Sao Paulo, Brazil  
Carles Conill. Barcelona, Spain  
Brigitte Dreno. Lyon, France  
Alexander Eggermont. Rotterdam, Netherlands  
Richard Essner. Los Angeles, USA  
Keith Flaherty. Philadelphia, USA  
Claus Garbe. Tübingen, Germany  
Pedro Gascón. Barcelona, Spain  
Jean-Jacques Grob. Marseille, France  
Nelleke Gruis. Leiden, Netherlands  
Axel Hauschild. Kiel, Germany  
Peter Hersey. Newcastle, Australia  
Ulrich Keilholz. Berlin, Germany  
John Kirkwood. Pittsburgh, USA  
Gilles Landmann. Sao Paulo, Brazil  
Stanley Leong. San Francisco, USA  
Paul Lorigan. Manchester, UK  
Josep Malvehy. Barcelona, Spain

Salvador Martín-Algarra. Barcelona, Spain  
Martin Mihm. Boston, USA  
Hubert Pehamberger. Vienna, Austria  
Giovanni Pelleciani. Modena, Italy  
Ketty Peris. L'Aquila, Italy  
Victor Prieto. Houston, USA  
Susana Puig. Barcelona, Spain  
Antoni Ribas. San Francisco, USA  
Jason Rivers. Vancouver, Canada  
Caroline Robert. Paris, France  
Merrick Ross. Houston, USA  
Dirk Schadendorf. Mannheim, Germany  
Stefania Seidenari. Modena, Italy  
Vernon Sondak. Tampa, USA  
Alexander Stratigos. Athens, Greece  
John Thompson. Sydney, Australia  
Hensin Tsao. Boston, USA  
Selma Ugurel. Würzburg, Germany  
Sergi Vidal-Sicart. Barcelona, Spain  
Matthias Volkenandt. Munich, Germany  
Iris Zalaudek. Graz, Austria

## Wednesday, 5 September 2007

- 12.00 **PRESESSION. New drugs and new studies**  
Chairpersons: Claus Garbe / Axel Hauschild
- 12.00 CTLA-4/PD-1 pathway in regulating T-cell response and clinical trial data  
Jeffrey Weber (inquired)
- 12.25 Heat shock protein 70 (STA4783). Steve O'Day (inquired)
- 12.50 Anti-integrin antibodies (CNT095). Dirk Schadendorf
- 13.15 RAF kinase inhibitors. Axel Hauschild
- 13.40 Sunitinib. Martin Gore (inquired)
- 14.05 Biomarkers. Selma Ugurel
- 15.00 **SATELLITE SYMPOSIUM I**
- 17.00 **SATELLITE SYMPOSIUM II**
- 20.00 Welcome Reception, Fundació Miró

## Thursday, 6 September 2007

- 08.15 **CASE PRESENTATIONS**  
Chairpersons: Susana Puig / Iris Zalaudek / Giovanni Pellacani
- 09.00 **PLENARY SESSION 1. Primary and secondary prevention of melanoma**  
Chairpersons: Jean-Jacques Grob / Jason Rivers  
Key Issues. How to achieve exchanges in the behaviour of the public in order to decrease melanoma incidence? Is nevus screening worthwhile?
- 09.00 The role of primary prevention in melanoma 2007. Jason Rivers
- 09.15 Risk factors for melanoma development. Alexander Stratigos
- 09.30 Low penetrance melanoma susceptibility genes. Ketty Peris
- 09.45 The GenoMEL Study of melanoma-prone families from three continents  
Nelleke Gruis
- 10.00 Nevus screening – Who should be screened and how should it be done?  
Jean-Jacques Grob
- 10.15 Statement of Chairpersons to Key Issues
- 10.25 Discussion
- 11.00 Coffee - Break
- 11.30 **BASIC LECTURE A. Genetics and genomics in melanoma**  
Hensin Tsao
- 12.15 Lunch / **POSTER VIEWING**
- 13.30 **BREAKOUT SESSIONS**
- 13.30 Dermoscopy and new techniques. Giuseppe Argenziano / Stefania Seidenari  
Genetic testing and patient counselling in melanoma  
Nelleke Gruis / Ketty Peris / Susana Puig  
Staging diagnostics – Present and future directions. Antonio Buzaid / Jürgen Becker  
Establishment of scientific tissue banks. Victor Prieto / Dirk Schadendorf
- 15.00 **PLENARY SESSION 2. Melanoma diagnosis**  
Chairpersons: Martin Mihm / Josep Malvehy  
Key Issues. Should dermoscopy become a standard in melanoma diagnosis? Which molecular markers should be included in future work up of melanoma specimens?
- 15.00 Dermoscopy in the diagnosis of initial melanomas. Giuseppe Argenziano
- 15.15 Challenges for dermoscopy and non invasive imaging in melanoma diagnosis  
Josep Malvehy
- 15.30 Digital dermoscopy. Stefania Seidenari

- 15.45 The use of tissue microarray as a tool to evaluate the importance of cell cycle proteins, integrins and metallo-proteinases in melanoma behaviour. Gilles Landmann
- 16.00 Molecular prognostic markers in melanoma. Martin Mihm
- 16.15 Statement of Chairpersons to Key Issues
- 16.25 Discussion
- 17.00 End of Session
- 17.00 Report from Breakout Sessions

## Friday, 7 September 2007

- 08.15 **CASE PRESENTATIONS**  
Chairpersons: Sergi Vidal-Sicart / Carles Conill
- 09.00 **PLENARY SESSION 3. Melanoma surgery**  
Chairpersons: Alexander Eggermont / Vernon Sondak  
Key Issues. What are the present standards in melanoma surgery?  
Should metastasectomy have a greater role in stage IV melanoma?
- 09.00 Surgical management of melanoma: Standards, new insights and the biology behind Alexander Eggermont
- 09.15 Shall we perform sentinel node biopsy if benefit for overall survival is lacking?  
Stanley Leong
- 09.30 Reversal of immune suppression in sentinel lymph nodes. Richard Essner
- 09.45 Role of surgical metastasectomy in stage IV melanoma. Vernon Sondak
- 10.00 Future directions of melanoma staging. Merrick Ross
- 10.15 Statement of Chairpersons to Key Issues
- 10.25 Discussion
- 11.00 Coffee - Break
- 11.30 **BASIC LECTURE B. Essentials of guideline development for melanoma**  
John Thompson
- 12.15 Lunch / **POSTER VIEWING**
- 13.30 **BREAKOUT SESSIONS**  
Is SLNB appropriate in 2007? If so, in which patients? Merrick Ross / Vernon Sondak  
Organization of melanoma centers/Study centers. Claus Garbe / John Thompson  
Investigator initiated trials. Ulrich Keilholz / Sanjiv Agarwala
- 15.00 **PLENARY SESSION 4. Targeted and individualized approaches to future melanoma therapy**  
Chairpersons: Keith Flaherty / Hubert Pehamberger  
Key Issues. Which are the most promising targets for future melanoma treatment?  
How can melanoma therapy be individualized?
- 15.00 Targeting signal transduction pathways in melanoma. Keith Flaherty
- 15.15 Molecular targets – Others than signal transduction proteins. Paul Lorigan
- 15.30 Targeting tumor apoptosis. Hubert Pehamberger
- 15.45 Sorafenib. Sanjiv Agarwala
- 16.00 How to individualize systemic therapies in melanoma. Jürgen Becker
- 16.15 Statement of Chairpersons to Key Issues
- 16.25 Discussion
- 17.00 End of Session
- 17.00 Report from Breakout Sessions



## Saturday, 8 September 2007

### 08.15 **CASE PRESENTATIONS**

Chairpersons: Pedro Gascón / Salvador Martín-Algarra

### 09.00 **PLENARY SESSION 5. Immunotherapy**

Chairpersons: Peter Hersey / Antoni Ribas

Key Issues. Does vaccination have a role in future melanoma treatment?  
How can different immunotherapeutic strategies be combined?

09.00 Melanoma vaccination with cell line derived antigens. Current results and perspectives  
Peter Hersey

09.15 Dendritic cell vaccination. Dirk Schadendorf

09.30 CTLA4 antibodies. Antoni Ribas

09.45 T-cell mediated melanoma treatment – How can it be developed? Brigitte Dreno

10.00 Cutaneous adverse events of new anti-cancer drugs. Caroline Robert

10.15 Statement of Chairpersons to Key Issues

10.25 Discussion

11.00 Coffee - Break

### 11.30 **BASIC LECTURE C. Communication with the cancer patient**

Matthias Volkenandt

12.15 Lunch / **POSTER VIEWING**

### 13.30 **BREAKOUT SESSIONS**

Documentation and quality control. John Thompson / Claus Garbe

Future directions of adjuvant melanoma treatment

Alexander Eggermont / John Kirkwood

Recommendations for first and second line treatment in stage IV melanoma

Keith Flaherty / Axel Hauschild

### 15.00 **PLENARY SESSION 6. Systemic treatment of melanoma**

Chairpersons: John Kirkwood / Axel Hauschild

Key Issues. Can general recommendation be given for adjuvant melanoma treatment?  
What is the recommendation for first and second line systemic melanoma  
treatment in stage IV disease?

15.00 What is the role of interferon-alpha in future melanoma treatment? – The US  
perspective. John Kirkwood

15.15 What is the role of interferon-alpha in future melanoma treatment? – The European  
perspective. Claus Garbe

15.30 Treatment of melanoma with cytotoxic drugs in the decade of targeted therapies  
Ulrich Keilholz

15.45 Has chemoimmuno-therapy a role in melanoma treatment? Antonio Buzaid

16.00 Overview on recent and ongoing clinical trials. Axel Hauschild

16.15 Statement of Chairpersons to Key Issues

16.25 Discussion

17.00 End of Session

17.00 Report from Breakout Sessions

## Congress Venue



**FIRA PALACE HOTEL** \*\*\*  
Av. Rius i Taulat, 1-3  
08004 Barcelona

**Dates** September 5-8, 2007

**Language and translation.** The official language of the meeting will be English. No simultaneous translation will be provided, except in the plenary sessions.

### Exhibition

A Commercial Exhibition will take place at the Congress Venue, in close proximity to the main meeting rooms. If you are interested in participating as exhibitor, please ask for more information to General Secretariat.

### Abstract submission - Deadline June 15<sup>th</sup>, 2007

If you wish to submit an abstract, please follow the instructions given at the Congress website [www.melanomacentersmeeting.com](http://www.melanomacentersmeeting.com)

### Registration and Hotel Accommodation

Please visit the Congress website for those purposes [www.melanomacentersmeeting.com](http://www.melanomacentersmeeting.com)

### Fees (VAT included)

	Early registration: June 15 <sup>th</sup>	From June 16 <sup>th</sup>	On site
Delegates	€ 300	€ 500	€ 600
Residents and Eastern Countries	€ 200	€ 350	€ 400
Accompanying person*	€ 100	€ 100	€ 150

\* Welcome Reception only

**After August 26<sup>th</sup>** all registrations will have to be **ON SITE**, at the Meeting Venue

**Registration fee includes:** entrance to the scientific sessions and to the Exhibition Area, documentation, coffee-breaks and admission to the Welcome Reception.

### Welcome Reception - Wednesday, 5 September

The Cocktail will be held in the Fundació Miró, the most important collection of Joan Miró's work. The Foundation enjoys a prime location overlooking the city from the magnificent vantage point of Montjuïc Park and also is meeting point where culture and leisure come together in a rich and varied series of spaces. Private visit to the Museum.

### Cancellation policy

From **January 1<sup>st</sup>** until **July 30<sup>th</sup>** a 50% refund. Between **August 1<sup>st</sup>** and **August 31<sup>st</sup>** a 25%. After **September 1<sup>st</sup>**, no refund.

The participant acknowledges that he/she has no right to lodge damage claims against the organizers should the holding of the meeting be hindered or prevented by unexpected, political or economic events or generally by force majeure, or should the nonappearance of speakers or other reasons need programme changes. With registration, the participant accepts this proviso.

### Insurance

The Organizer do not accept liability for individual medical, travel or personal insurance and participants are strongly advised to make their own arrangements in respect to health and travel insurance.

### Passport and visa

Identity card is required to entry in Spain for people from EEC countries. For people from non EEC countries a valid passport is required. A visa may be required for some countries. For information about visa and passports contact the Spanish embassy in your country at least 3 months prior to your departure to Spain.

## Main Sponsors

Platinum  Schering-Plough

Gold



Bayer HealthCare  
Bayer Schering Pharma

Silver



General  
Secretariat



Apartado Correos 14.040 Tel. +34 690 846 097  
08080 Barcelona, Spain Fax +34 932 057 230

[sbc@sbc-congresos.com](mailto:sbc@sbc-congresos.com) [www.melanomacentersmeeting.com](http://www.melanomacentersmeeting.com)